Vorinostat (SAHA) is a potent inhibitor of Classes I and II histone deacetylases (HDACs) that works by chelating Zinc ions found in the active site of HDACs. Vorinostat's inhibition of HDAC activity results in the accumulation of acetylated histones and acetylated proteins, including transcription factors crucial for the expression of genes needed to induce cell differentiation.

Vorinostat inhibits the proliferation of both normal cells and a wide variety of transformed cells. It induces death in tumor cells while leaves normal cells alive. Vorinostat inhibits tumor growth in a variety of animal models¹. Marketed under the name Zolinza, Vornostat is a FDA approved medicine for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat is now under clinical investigations for several other types of cancers and for its potential use in eradicating HIV from HIV+ patients^2,3.

Vorinostat (SAHA) is a potent inhibitor of Classes I and II histone deacetylases (HDACs) that works by chelating Zinc ions found in the active site of HDACs. Vorinostat's inhibition of HDAC activity results in the accumulation of acetylated histones and acetylated proteins, including transcription factors crucial for the expression of genes needed to induce cell differentiation.

Vorinostat inhibits the proliferation of both normal cells and a wide variety of transformed cells. It induces death in tumor cells while leaves normal cells alive. Vorinostat inhibits tumor growth in a variety of animal models¹. Marketed under the name Zolinza, Vornostat is a FDA approved medicine for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat is now under clinical investigations for several other types of cancers and for its potential use in eradicating HIV from HIV+ patients^2,3.